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Abstract
Objective
To assess whether prediagnostic levels of plasma branched-chain amino acids (BCAAs) are
associated with amyotrophic lateral sclerosis (ALS) risk.
Methods
We included participants from 5 large cohort studies—The Nurses’ Health Study, the Health
Professionals Follow-up Study, the Cancer Prevention Study II Nutrition, the Multiethnic
Cohort Study, and the Women’s Health Initiative—and identiﬁed 275 individuals who de-
veloped ALS during follow-up. Two controls were randomly selected for each case, matched on
cohort, age, sex, fasting status, and time of blood draw. We measured metabolites using liquid
chromatography–mass spectrometry and used conditional logistic regression to estimate rate
ratios (RRs) and 95% conﬁdence intervals (CIs) for the association of individual BCAAs with
ALS risk.
Results
None of the 3 BCAAs was associated with a higher ALS risk. The risk estimates were similar for
leucine (RR top vs bottom quartile: 0.87, 95% CI 0.57–1.33), isoleucine (RR top vs bottom
quartile: 0.81, 95% CI 0.52–1.24), and valine (RR top vs bottom quartile: 0.80, 95% CI
0.52–1.23) in a multivariable analysis adjusted for body mass index, smoking, level of education,
and physical activity. The estimates did not vary signiﬁcantly by sex, fasting status, or time
interval between blood draw and disease onset.
Conclusion
The results from this study do not support the hypothesis that BCAAs are risk factors for ALS.
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The branched-chain amino acids (BCAAs) valine, leucine, and
isoleucine play an important role in glutamate metabolism,1
which has been implicated in the pathogenesis of amyotrophic
lateral sclerosis (ALS).2 As BCAAs have been postulated to
restore impaired glutamate metabolism,3 the eﬀect of these
essential amino acids on ALS progression has been explored in
clinical trials. Several of these have, however, not only failed to
support a beneﬁcial role of BCAAs but provided evidence for
potential adverse eﬀects. In an Italian trial, there was an excess
of deaths in the group treated with BCAAs,4 and in a later US
trial, the estimated decline in forced vital capacity, one of the
a priori selected outcomes, was 2.5 times greater in the treat-
ment group as compared to placebo.5 As BCAAs may aﬀect
pathways relevant to ALS, including downregulation of anti-
oxidant genes associated with familial ALS and induction of
hyperexcitability in cortical neurons,6,7 it has been proposed
that dietary supplements containing BCAAs, which are com-
monly used by Italian soccer players,8 could be one of the
factors that contributed to their elevated ALS risk.9,10
Whether BCAAs increase the risk of ALS is currently not
known. Higher levels have been reported in patients with ALS
compared to controls,11,12 but as the amino acids’ concen-
trations may have been aﬀected by the disease itself, it is
unclear whether they are etiologically relevant. Prospective
studies including prediagnostic samples from individuals later
developing ALS could be more informative, but they are
diﬃcult to conduct due to the low incidence of the disease.
To address this, we conducted a pooled analysis of 5 large
prospective cohort studies to assess whether higher pre-
diagnostic plasma levels of BCAAs are associated with an
increased ALS risk.
Methods
Study populations
The study population included participants from 5 large co-
hort studies: The Nurses’ Health Study (NHS), the Health
Professionals Follow-up Study (HPFS), the Cancer Pre-
vention Study II Nutrition Cohort (CPS-II Nutrition), the
Multiethnic Cohort Study (MEC), and the Women’s Health
Initiative (WHI). Detailed descriptions of the individual
cohorts have previously been published.13–17 In short, the
NHS began in 1976 with 121,700 female nurses aged 30–55
years at baseline.13 In 1988, all nurses were invited to provide
a blood sample, which was collected from 32,826 women
during 1989 and 1990. Thirty-nine nurses who gave a blood
sample developed ALS between blood draw and end of
follow-up. TheHPFS began in 1986 and enrolled 51,529 male
health professionals aged 40–75 years at baseline.14 All of the
participants were invited to provide a blood sample, which
was collected from 18,018 men between 1993 and 1995.
Twenty-six men were identiﬁed with ALS between blood
draw and end of follow-up. Every 2 years, the participants in
these 2 cohorts were followed up with similar questionnaires
on medical history and health-related behavior. The CPS-II
Nutrition cohort was established in 1992 and consists of
a subpopulation of the larger CPS-II cohort.15 It includes
86,406 men and 97,788 women aged 50–74 years at baseline.
These participants completed a questionnaire on lifestyle and
dietary factors at baseline, in 1997 and biennially thereafter. In
1998, participants living in urban and suburban areas were
invited to provide a blood sample, which was collected from
39,380 members of the cohort. Among these, 58 participants
died of ALS during follow-up. The MEC cohort study began
in 1993 and consists of 96,810 men and 118,441 women aged
45–75 years at baseline with the self-reported ethnic back-
ground of African American, Japanese American, Latino,
Native Hawaiian, or white.16 The participants completed
a lifestyle and disease history questionnaire at baseline, and
follow-up questionnaires every 5 years thereafter. A total of
67,594 members of the cohort provided a blood sample,
which was largely collected between 2001 and 2006. Thirty-
one participants died of ALS between blood draw and end of
follow-up. The WHI study recruited a total of 161,809 post-
menopausal women aged 50–79 years between 1993 and
1998, who were enrolled into one ormore of 3 clinical trials (n
= 68,133) or into the observational study (n = 93,676).17 At
baseline, all of the participants completed a questionnaire on
lifestyle and disease history and provided a blood sample. A
total of 121 participants died of ALS after blood draw until
end of follow-up. End of follow-up was December 31, 2010,
for NHS, HPFS, and CPS-II Nutrition; September 30, 2012,
for WHI; and December 31, 2012, for MEC.
Standard protocol approvals, registrations,
and patient consents
All of the studies included were reviewed and approved by the
institutional review board at the institution where each study
was conducted.
Endpoint definition
In the CPS-II Nutrition,MEC, andWHI studies, we identiﬁed
ALS cases through a search of the National Death Index. WHI
Glossary
ALS = amyotrophic lateral sclerosis; BCAA = branched-chain amino acids; BMI = body mass index; CI = conﬁdence interval;
CPS-II Nutrition = Cancer Prevention Study II Nutrition Cohort; HPFS = Health Professionals Follow-up Study; ICD-9 =
International Classiﬁcation of Diseases, Ninth Revision; MEC = Multiethnic Cohort Study; NHS = Nurses’ Health Study;
NMR = nuclear magnetic resonance;OR = odds ratio;PPV = positive predictive value;RR = rate ratio;WHI =Women’s Health
Initiative.
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also compiled self-reported ALS information for women in
the observational study, but it was never adjudicated. All
individuals with ICD-9 code 335.2 (motor neuron disease)
listed as the underlying or contributing cause of death were
considered to have had ALS. In a previous validation study,
ALS was the primary diagnosis in 90% of the individuals for
whom code 335.2 was listed as the cause or contributory cause
of death.18 We assigned the date of onset to 3 years before the
date of death, based on median survival among patients with
ALS.19
In the NHS and HFPS, we identiﬁed incident ALS by self-
report on the biennial questionnaire. For participants
reporting a diagnosis of ALS, we requested permission to
contact the treating neurologist and obtain a copy of the
medical records. Due to the progressive nature of ALS, many
of the patients had already died before we could obtain
permission to release the medical records. For these patients,
we sent the request to the closest family member. We asked
the treating neurologist to complete a questionnaire, which
was based on the revised El Escorial criteria, on the certainty
of the diagnosis (deﬁnite, probable, or possible), and the
clinical history. The ﬁnal conﬁrmation of the diagnosis was
made after reviewing medical records by a neurologist with
experience in ALS diagnosis. We observed few discrepancies
between the diagnosis made by the ﬁeld neurologist and the
neurologist with expertise in ALS, and the diﬀerences were
mostly limited to whether patients were diagnosed with
deﬁnite or probable ALS. Patients deﬁned as deﬁnite or
probable cases were included in the study. If we were unable
to obtain a copy of the medical record or the neurologist’s
questionnaire to conﬁrm the diagnosis of self-reported ALS,
only the patients with ALS speciﬁcally listed on the death
certiﬁcate were included.
For each ALS case, we randomly selected 2 controls who were
alive at the time of the case diagnosis and matched on cohort,
birth year (±1 year), sex, ethnicity, fasting status, and time of
blood draw. For one of the cases, only one matched control
was included in the ﬁnal analyses, as the assessment of
metabolites failed in the other matched control.
Assessment of metabolites
Across the cohorts, blood samples were collected from
a total of 319,627 participants and were stored at −70°C or
below. For the individuals who developed ALS and their
matched controls, 10 μL of plasma from each individual was
used for the metabolomics analysis. Triplets of plasma
samples (one case with its 2 matched controls) were handled
identically and assayed in the same analytic run. The order of
the plasma samples within each case–control tripled was
arranged at random, to ensure that all assays were conducted
without knowledge of the case/control status. We proﬁled
the metabolites using hydrophilic interaction liquid chro-
matography coupled to positive ion mode mass spectrom-
etry at the Broad Institute (Boston, MA), as previously
described.20
Assessment of covariates
Information on other covariates of interest, including
smoking status, height, weight, educational level, physical
activity, and diabetes status, was collected at baseline for all
cohorts, and every 2 years since baseline in HPFS and NHS.
Participants self-reported a diagnosis of type 1 or type 2
diabetes mellitus. These speciﬁc covariates were included in
multivariable models, as they have previously been associ-
ated with ALS risk, and could be potential confounders. The
nearest covariate data collected before or at the time of blood
draw were used.
Statistical analysis
To account for the matched study design, we used condi-
tional logistic regression to estimate odds ratios (ORs) and
95% conﬁdence intervals (CIs) for the association of BCAAs
with ALS risk. As controls in our study were selected using
risk-set sampling, the ORs estimate incidence rate ratios
(RRs).21 We log-transformed and standardized the amino
acids within cohort and sex to account for possible diﬀer-
ences that may have been introduced as cohort samples were
processed at diﬀerent times. We estimated the correlation
between log-transformed levels of individual BCAAs, glu-
tamate, urate, and body mass index (BMI) using Pearson
correlation, and tested whether the BCAAs were signiﬁ-
cantly diﬀerent among diabetic and nondiabetic participants
using a 2-sided t test. The amino acids were modeled as both
continuous (per 1 SD increase) and categorical variables to
maximize power and to explore possible nonlinear rela-
tionships. For the categorical analyses, we categorized the
participants into cohort and sex-speciﬁc quartiles based on
the distribution among the controls. We tested for a linear
trend across the quartiles by assigning the median value to
each quartile and modeled this as a continuous variable.
Multivariable models were used to assess the inﬂuence of
possible confounders, including BMI (using weight reported
closest to time of blood draw, continuous), educational level
(< high school, high school, > high school), smoking status
(never smoker, past smoker, current smoker), and physical
activity (approximate tertiles corresponding to low, medium,
and high activity levels). We categorized participants
according to tertiles of metabolic equivalent hours of total
physical activity in NHS, HPFS, and WHI, while the amount
of moderate and vigorous physical activity was used for CPS-
II andMEC.When data were missing for a covariate, we used
a missing indicator (6.7% of the participants had 1 or more
missing covariate data). We tested for eﬀect modiﬁcation by
sex, fasting status (<4 vs ≥4 hours since last meal), and time
from blood collection to disease onset (<5 vs ≥5 years) by
including a product term of individual BCAAs and the
modiﬁer in separate models. We conducted a sensitivity
analysis excluding individuals with diabetes, as diabetes has
been associated with marked alterations in the metab-
olome,22 including elevated BCAA levels,23 and has also
been associated with the risk of ALS.24 All of the analyses
were conducted using SAS 9.4 (SAS Institute, Cary, NC).
The α-level was set at 0.05.
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Data availability
The datasets analyzed in the current study are not publicly
available because of restricted access, but further information
about the datasets is available from the corresponding author
on reasonable request.
Results
We identiﬁed a total of 275 individuals who developed ALS
among the 319,627 participants who provided blood samples
in these 5 cohort studies. There was a higher proportion of
female compared to male participants in our study. The cases
were slightly more likely to have ever smoked compared to
controls and had slightly lower BMI at baseline (table 1).
Further, fewer cases had higher educational level than high
school compared to the controls. The other characteristics were
similarly distributed. Plasma levels of leucine, isoleucine, and
valine correlated signiﬁcantly with each other, and higher levels
correlated with higher BMI (table 2). Further, higher levels of
the amino acids correlated signiﬁcantly with higher levels of
glutamate and with urate. The levels of all 3 BCAAs were
higher among diabetic compared to nondiabetic participants
(p = 0.006, p = 0.004, and p < 0.001 by the t test for leucine,
isoleucine, and valine, respectively).
Higher levels of valine were associated with a lower ALS risk
in analyses adjusted for age, sex, and matching variables, but
the trend was not monotonic and was no longer statistically
signiﬁcant after further adjustment for BMI. Other BCAAs
were not signiﬁcantly associated with ALS risk, neither in the
continuous nor in the categorical analyses (table 3). Adjust-
ment for BMI, smoking, physical activity, and educational
level did not materially alter the results. Total BCAA plasma
level was not associated with ALS risk (data not shown).
None of the 3 metabolites was signiﬁcantly associated with
ALS risk in any of the predeﬁned subgroup analyses (table 4).
The RR estimates were slightly lower in women compared to
men, but the diﬀerence was not signiﬁcant. Similarly, the
estimates were lower among those with fasting samples
compared to those with nonfasting samples, but the estimates
were not statistically signiﬁcantly diﬀerent. The estimates
from analyses restricted to those with longer interval (≥5
years) between blood draw and ALS onset were similar to
those restricted to those with shorter interval (<5 years). The
results were similar when we restricted the analyses to indi-
viduals with an interval of 2 years or less between blood draw
and ALS onset (data not shown).
In a sensitivity analysis, we excluded participants who had
developed diabetes before the blood draw, as insulin re-
sistance has been associated with increased BCAA levels and
diabetes has been suggested to aﬀect ALS risk.23,24 However,
none of the 3 BCAAs was associated with ALS risk when
excluding patients with diabetes (n = 49). In a multivariable
model adjusting for age, sex, BMI, smoking, physical activity,
and educational level, the RR for ALS per 1 SD increase in
amino acid levels was 0.88 (95% CI 0.76–1.03) for leucine,
0.92 (95% CI 0.78–1.08) for isoleucine, and 0.87 (95% CI
0.75–1.02) for valine.
Discussion
In this pooled analysis of 5 large cohort studies, we did not
ﬁnd any association between prediagnostic plasma levels of
BCAAs and the risk of ALS. The results did not vary signiﬁ-
cantly with time to ALS onset and were not materially
changed when we adjusted for the most relevant confounders.
Our ﬁndings do not support the hypothesis that plasma
BCAAs are risk factors for ALS.
Previous research on BCAAs and ALS risk is sparse, and no
study has previously evaluated the association between pre-
diagnostic plasma levels and disease risk. Some,11,12,25 but not
all,26,27 studies comparing the metabolome in patients with
ALS with controls reported alterations in the metabolism of
BCAAs in patients. In a study comparing the metabolome in
22 patients with ALS with 28 controls with other neurologic
conditions, the plasma levels of all 3 BCAAs were higher in
patients with ALS compared to controls in analyses using
nuclear magnetic resonance (NMR) spectroscopy.11 The
results were similar in a study comparing the metabolome in
the same cohort of patients and controls using mass spec-
trometry, but only plasma levels of valine and isoleucine were
signiﬁcantly increased in patients with ALS.12 Further, one
study used NMR to try to identify a diagnostic proﬁle dis-
criminating 95 patients with motor neuron disease from 86
patients with other neurologic diseases and reported that
valine and isoleucine measured in the CSF were among the
metabolites contributing most to the ﬁnal diagnostic model.25
In our study, we did not ﬁnd any diﬀerences in prediagnostic
BCAA levels in those later developing ALS compared to their
matched controls, which indicates that the amino acids do not
contribute to the earliest etiologic events. Still, it is possible
that these amino acids aﬀect disease processes at a later stage,
which could be consistent with the results from previous
metabolomics studies, the possible adverse eﬀects reported in
clinical trials,4,5 and the ﬁndings from in vivo and in vitro
studies suggesting that BCAAs aﬀect pathways relevant to the
disease.6,7
BCAAs contribute both to de novo synthesis and buﬀering of
glutamate, which in excessive amounts may contribute to
excitotoxicity in ALS. The amino acids, in particular leucine,
rapidly cross into the CNS,28 and provide approximately 25%
of the amino groups of brain glutamate.29 It has been sug-
gested that high levels of BCAAs lead to an excess of gluta-
mate, which could trigger motor neuron death due to
excessive stimulation of glutamate receptors.30 This is sup-
ported by evidence from an animal study where a diet
enriched in BCAAs induced a hyperexcitability of motor
neurons, which was related to a speciﬁc glutamate receptor
(NMDA receptor), as the eﬀect was abolished after
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Table 1 Selected age-standardized characteristics
Characteristics Cases (n = 275) Controls (n = 549) p Value
Age, y a
Mean (SD) 64.6 (7.2) 64.6 (7.2) —
Sex, n (%)a
Male 75 (27.3) 150 (27.3) —
Female 200 (72.7) 399 (72.7)
Fasting status, h, n (%)a
<4 73 (26.6) 155 (28.2) —
≥4 202 (73.5) 394 (71.8)
Interval from blood draw to ALS onset, y a
Median (IQR) 4.8 (1.9–7.8) — —
<5, n (%) 144 (52.4) — —
≥5, n (%) 131 (47.6) — —
Body mass index
Mean (SD) 26.2 (4.4) 26.9 (5.2) 0.034
Smoking status, n (%)a 0.82
Never smoker 123 (44.7) 264 (48.1)
Past smoker 128 (46.6) 239 (43.5)
Current smoker 18 (6.6) 36 (6.6)
Unknown 6 (2.2) 10 (1.8)
Ethnicity, n (%)a 0.98
White 225 (81.8) 448 (81.6)
African American 21 (7.6) 39 (7.1)
Hispanic 8 (2.9) 17 (3.1)
Asian 10 (3.6) 20 (3.6)
Other 6 (2.2) 17 (3.1)
Not reported 5 (1.8) 8 (1.5)
Education, n (%)a 0.50
< High school 13 (4.8) 20 (3.7)
High school 48 (17.7) 84 (15.4)
> High school 211 (77.6) 442 (81.0)
Physical activity, n (%)a 0.99
Low levels 87 (32.8) 175 (33.0)
Medium level 79 (29.8) 157 (29.6)
High level 99 (37.4) 199 (37.5)
Diabetes, n (%) 0.46
Yes 14 (5.1) 35 (6.4)
No 261 (94.9) 514 (93.6)
Abbreviation: IQR = interquartile range.
Values are standardized to the age distribution of the study population. Values of polytomous variablesmay not sumup to 100%due to rounding. pValues are
not given for matching factors (age, sex, and fasting status), as these are similar in the 2 groups by design.
a Value is not age-adjusted.
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administration of a speciﬁc NMDA channel blocker.31
However, BCAAs also serve as a buﬀering mechanism
against excessive glutamate levels. After BCAAs are me-
tabolized in astrocytes, their ketoacids are released into the
extracellular ﬂuid and can subsequently be taken up by
neurons.1 Ketoleucine can be converted back to leucine in
a process that consumes glutamate, which provides
a mechanism for preventing excessive amounts of the
amino acid.1 It is thus unclear whether higher BCAA intake
in humans would lead to levels of glutamate that could have
neurotoxic eﬀects.
Our study has several strengths. First, the nested case-control
study design, where the participants were drawn from existing
cohort studies, minimizes the risk of selection bias when
choosing the controls. Second, the prospective study design
with samples collected years before disease onset limits the
risk of reverse causation bias. Finally, we were able to account
for several possible confounders suggested to be relevant in
ALS, including BMI, physical activity, smoking, and diabetes.
Our study also has some limitations. While we drew partic-
ipants from 5 large cohort studies, we were able to identify
Table 2 Pearson correlation coefficients for individual branched-chain amino acids, urate, and body mass index (BMI)
Leucine Isoleucine Valine Glutamate Urate
Isoleucine 0.936a
Valine 0.894a 0.862a
Glutamate 0.333a 0.317a 0.319a
Urate 0.158a 0.169a 0.188a 0.197a
BMI 0.206a 0.224a 0.272a 0.227a 0.302a
a p < 0.001 (2-tailed).
Table 3 Rate ratio (RR) for amyotrophic lateral sclerosis according to prediagnostic branched amino acid plasma levels
Incident cases (275 cases, 549 noncases)
RR (95% CI)
Leucine Isoleucine Valine
Model 1a
Per SD 0.88 (0.76–1.02) 0.90 (0.78–1.04) 0.86 (0.75–0.99)
Across quartiles
Q1 1 (reference) 1 (reference) 1 (reference)
Q2 0.81 (0.54–1.23) 0.77 (0.51–1.15) 0.78 (0.52–1.16)
Q3 0.67 (0.44–1.01) 0.72 (0.48–1.07) 0.51 (0.33–0.78)
Q4 0.81 (0.54–1.23) 0.74 (0.49–1.11) 0.72 (0.48–1.09)
p For trend 0.23 0.13 0.046
Model 2b
Per SD 0.90 (0.78–1.05) 0.93 (0.80–1.09) 0.89 (0.77–1.04)
Across quartiles
Q1 1 (reference) 1 (reference) 1 (reference)
Q2 0.85 (0.56–1.29) 0.80 (0.53–1.21) 0.80 (0.53–1.20)
Q3 0.72 (0.47–1.09) 0.77 (0.51–1.16) 0.54 (0.35–0.83)
Q4 0.87 (0.57–1.33) 0.81 (0.52–1.24) 0.80 (0.52–1.23)
p For trend 0.40 0.29 0.14
Abbreviation: CI = confidence interval.
a Model 1: adjusted for age, sex, and matching variables.
b Model 2: additional adjustment for body mass index, smoking, level of education, and physical activity.
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only 275 individuals who later developed ALS, due to the low
incidence of the disease. This may have aﬀected the statistical
power to detect signiﬁcant diﬀerences, especially in subgroup
analyses. Still, given that risk estimates for all of the BCAAs
with ALS risk were below 1.0, it seems unlikely that the amino
acids would be associated with an increased risk if a higher
number of participants had been included. Our study pop-
ulation only included 27%male participants, which represents
an atypical ALS population, as the incidence rate of the disease
is higher in men compared to women.32 The unusual distri-
bution is mainly due to the inclusion of participants from
WHI, who are all female and all contributed with blood
samples. We did not observe any signiﬁcant diﬀerences in the
results in men and women, and it is therefore unlikely that this
has aﬀected our results. We did not have information on
clinical covariates, such as subtypes of ALS, and could
therefore not evaluate whether there were diﬀerences be-
tween those developing familial ALS to those with sporadic
ALS. Further, due to lack of clinical information, we used
information from death certiﬁcates to capture ALS cases in
CPS-IIN, MEC, and WHI. This may have led to mis-
classiﬁcation of ALS in some participants, as death certiﬁcates
are likely to be less accurate than medical records. In a US
study, the sensitivity and positive predictive value (PPV) for
use of death certiﬁcates for ALS were estimated to be 85% and
65%,33 while a recent study from Denmark reported a sensi-
tivity of 84% and an overall PPV of 82%.34 Overall, this sug-
gests that use of death certiﬁcates is an adequate, but not ideal,
tool to capture patients with ALS in epidemiologic studies.
We assessed the association using a single plasma
measurement per individual, which may not reﬂect long-term
exposure of the amino acids over time. However, in a valida-
tion study in NHS and HPFS, the 3 amino acids had Spear-
man correlations above 0.60 when comparing 2 samples
collected in the same individuals 0.8–2.3 years apart, in-
dicating that a single measurement may reasonably reﬂect
longer-term levels.35 As data on physical activity were col-
lected at diﬀerent ages and with diﬀerent methodologies
across the cohorts, we may not have been able to fully adjust
for this in the analyses. Finally, as is inherent to any obser-
vational study, we cannot exclude the possibility that the
results may be aﬀected by residual or unmeasured con-
founding that we cannot account for.
In a pooled analysis of 5 cohort studies, we did not ﬁnd any
signiﬁcant association between prediagnostic plasma levels of
BCAAs and ALS risk. Our ﬁndings suggest that high physi-
ologic levels of these amino acids do not increase the risk of
the disease.
Author contributions
Dr. Bjornevik: drafting/revising the manuscript for content,
analysis or interpretation of data, statistical analysis. Dr.
O’Reilly: drafting/revising the manuscript for content, anal-
ysis or interpretation of data. Dr. Berry: drafting/revising the
manuscript for content, analysis or interpretation of data. Dr.
Clish: drafting/revising the manuscript for content, analysis
or interpretation of data. S. Jeanfavre: drafting/revising the
manuscript for content, analysis or interpretation of data. Dr.
Kato: drafting/revising the manuscript for content,
Table 4 Rate ratio (RR) for amyotrophic lateral sclerosis (ALS) according to prediagnostic branched amino acid plasma
levels in specific subgroups
Subgroup
RR per 1 SD increase (95% CI)a
Leucine Isoleucine Valine
Sex
Female 0.87 (0.72–1.04) 0.87 (0.72–1.05) 0.87 (0.73–1.05)
Male 0.96 (0.72–1.28) 1.04 (0.78–1.38) 0.92 (0.67–1.25)
p For interaction 0.35 0.15 0.64
Fasting status, h
<4 1.15 (0.82–1.59) 1.12 (0.80–1.56) 1.14 (0.83–1.57)
≥4 0.83 (0.69–1.01) 0.88 (0.72–1.07) 0.85 (0.70–1.03)
p For interaction 0.10 0.23 0.14
Interval between blood draw and ALS onset, y
<5 0.92 (0.75–1.13) 1.01 (0.81–1.25) 0.83 (0.67–1.04)
≥5 0.87 (0.70–1.09) 0.86 (0.69–1.08) 0.93 (0.75–1.16)
p For interaction 0.69 0.28 0.61
Abbreviation: CI = confidence interval.
a Adjusted for age, sex, body mass index, smoking, level of education, physical activity, and matching factors.
Neurology.org/N Neurology | Volume 92, Number 18 | April 30, 2019 e2087
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
acquisition of data. Dr. Kolonel: drafting/revising the manu-
script for content, acquisition of data. Dr. Le Marchand:
drafting/revising the manuscript for content, acquisition of
data. Dr. McCullough: drafting/revising the manuscript for
content, acquisition of data. Dr. Paganoni: drafting/revising
the manuscript for content, analysis or interpretation of data.
Dr. Schwarzschild: drafting/revising the manuscript for con-
tent, analysis or interpretation of data. Dr. Talbott: drafting/
revising the manuscript for content, acquisition of data.
Robert B. Wallace: drafting/revising the manuscript for con-
tent, acquisition of data. Dr. Zhang: drafting/revising the
manuscript for content, analysis or interpretation of data. Dr.
Manson: drafting/revising the manuscript for content, ac-
quisition of data. Dr. Ascherio: study concept or design,
drafting/revising the manuscript for content, analysis or in-
terpretation of data, acquisition of data, obtaining funding.
Drs. Bjornevik and Ascherio had full access to all the data in
the study and take responsibility for the integrity of the data
and the accuracy of the data analysis.
Acknowledgment
The authors acknowledge the cohorts’ participants and Leslie
Unger for administrative support.
Study funding
This work was supported by a grant from the National In-
stitute of Neurologic Diseases and Stroke (R01 NS045893)
awarded to Alberto Ascherio. The NHS is funded by the NIH
through grants UM1 CA186107 and R01 CA49449. The
HPFS cohort is funded by the NIH through grant UM1
CA167552. The American Cancer Society funds the creation,
maintenance, and updating of the CPS-II cohorts. The MEC
cohort is funded by the NIH through U01 CA164973. The
WHI program is funded by the National Heart, Lung, and
Blood Institute, NIH, US Department of Health and
Human Services, through contracts HHSN268201600018C,
HHSN268201600001C, and HHSN268201600002C. The
sponsors had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the
data; or preparation, review, or approval of the manuscript.
Disclosure
The authors report no disclosures relevant to the manuscript.
Go to Neurology.org/N for full disclosures.
Publication history
Received by Neurology April 6, 2018. Accepted in ﬁnal form September
17, 2018.
References
1. YudkoﬀM, Daikhin Y, Nissim I, et al. Brain amino acid requirements and toxicity: the
example of leucine. J Nutr 2005;135:1531S–1538S.
2. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in
amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 1990;28:3–8.
3. Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in
amyotrophic lateral sclerosis. Lancet 1988;1:1015–1018.
4. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral
sclerosis: a treatment failure? Neurology 1993;43:2466–2470.
5. Tandan R, BrombergMB, Forshew D, et al. A controlled trial of amino acid therapy in
amyotrophic lateral sclerosis: I: clinical, functional, and maximum isometric torque
data. Neurology 1996;47:1220–1226.
6. Piscopo P, Crestini A, Adduci A, et al. Altered oxidative stress proﬁle in the cortex of
mice fed an enriched branched-chain amino acids diet: possible link with amyotrophic
lateral sclerosis? J Neurosci Res 2011;89:1276–1283.
7. Carunchio I, Curcio L, Pieri M, et al. Increased levels of p70S6 phosphorylation in the
G93A mouse model of amyotrophic lateral sclerosis and in valine-exposed cortical
neurons in culture. Exp Neurol 2010;226:218–230.
8. Taioli E. Use of permitted drugs in Italian professional soccer players. Br J Sports Med
2007;41:439–441.
9. Chio A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyo-
trophic lateral sclerosis among Italian professional football players. Brain 2005;128:
472–476.
10. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian pro-
fessional soccer players: the risk is still present and could be soccer-speciﬁc. Amyo-
troph Lateral Scler 2009;10:205–209.
11. Wu JF, Wuolikainen A, Trupp M, et al. NMR analysis of the CSF and plasma
metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson’s disease
and control subjects. Metabolomics 2016;12.
12. Wuolikainen A, Jonsson P, Ahnlund M, et al. Multi-platform mass spectrometry
analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral
sclerosis, Parkinson’s disease and control subjects. Mol Biosyst 2016;12:1287–1298.
13. Bao Y, Bertoia ML, Lenart EB, et al. Origin, methods, and evolution of the three
nurses’ health studies. Am J Public Health 2016;106:1573–1581.
14. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol con-
sumption and risk of coronary disease in men. Lancet 1991;338:464–468.
15. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Pre-
vention Study II Nutrition cohort: rationale, study design, and baseline characteristics.
Cancer 2002;94:2490–2501.
16. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los
Angeles: baseline characteristics. Am J Epidemiol 2000;151:346–357.
17. Anderson GL, Manson J, Wallace R, et al. Implementation of the women’s health
initiative study design. Ann Epidemiol 2003;13:S5–S17.
18. Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A.
Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epi-
demiol 2004;160:26–33.
19. Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of
amyotrophic lateral sclerosis: analysis of a clinic population, 1997–2011. Neurol Clin
Pract 2013;3:313–320.
20. Paynter NP, Balasubramanian R, Giulianini F, et al. Metabolic predictors of incident
coronary Heart disease in women. Circulation 2018;137:841–853.
21. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies esti-
mate? Survey of methods and assumptions in published case-control research. Am J
Epidemiol 2008;168:1073–1081.
22. Guasch-Ferre M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes:
a systematic review and meta-analysis. Diabetes Care 2016;39:833–846.
23. Mahendran Y, Jonsson A, Have CT, et al. Genetic evidence of a causal eﬀect of insulin
resistance on branched-chain amino acid levels. Diabetologia 2017;60:873–878.
24. Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG.
Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a pop-
ulation-based study. JAMA Neurol 2015;72:905–911.
25. Blasco H, Nadal-Desbarats L, Pradat PF, et al. Untargeted 1H-NMRmetabolomics in
CSF: toward a diagnostic biomarker for motor neuron disease. Neurology 2014;82:
1167–1174.
26. Lawton KA, CudkowiczME, BrownMV, et al. Biochemical alterations associated with
ALS. Amyotroph Lateral Scler 2012;13:110–118.
27. Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to
distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyo-
troph Lateral Scler Frontotemporal Degener 2014;15:362–370.
28. Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid
transport across the blood-brain barrier. J Neurochem 1987;49:1651–1658.
29. Kanamori K, Ross BD, Kondrat RW. Rate of glutamate synthesis from leucine in rat
brain measured in vivo by 15N NMR. J Neurochem 1998;70:1304–1315.
30. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and
amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:147–159.
31. Contrusciere V, Paradisi S, Matteucci A, Malchiodi-Albedi F. Branched-chain amino
acids induce neurotoxicity in rat cortical cultures. Neurotox Res 2010;17:392–398.
32. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;
377:942–955.
33. Stickler DE, Royer JA, Hardin JW. Accuracy and usefulness of ICD-10 death
certiﬁcate coding for the identiﬁcation of patients with ALS: results from the
South Carolina ALS Surveillance Pilot Project. Amyotroph Lateral Scler 2012;13:
69–73.
34. KioumourtzoglouMA, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG.
Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certiﬁcates
and hospital discharge data in the Danish population. Amyotroph Lateral Scler
Frontotemporal Degener 2015;16:224–229.
35. Townsend MK, Clish CB, Kraft P, et al. Reproducibility of metabolomic proﬁles
among men and women in 2 large cohort studies. Clin Chem 2013;59:1657–1667.
e2088 Neurology | Volume 92, Number 18 | April 30, 2019 Neurology.org/N
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/WNL.0000000000006669
2019;92;e2081-e2088 Published Online before print November 14, 2018Neurology 
Kjetil Bjornevik, Éilis J. O'Reilly, James D. Berry, et al. 
sclerosis
Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral
This information is current as of November 14, 2018
Services
Updated Information &
 http://n.neurology.org/content/92/18/e2081.full
including high resolution figures, can be found at:
References
 http://n.neurology.org/content/92/18/e2081.full#ref-list-1
This article cites 34 articles, 9 of which you can access for free at: 
Subspecialty Collections
 http://n.neurology.org/cgi/collection/risk_factors_in_epidemiology
Risk factors in epidemiology
 http://n.neurology.org/cgi/collection/cohort_studies
Cohort studies
 http://n.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis_
Amyotrophic lateral sclerosis
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://www.neurology.org/about/about_the_journal#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://n.neurology.org/subscribers/advertise
Information about ordering reprints can be found online:
rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
